(STM-03) Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 May 2017
At a glance
- Drugs PAC 1 (Primary)
- Indications Haematological malignancies; Lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Vanquish Oncology
- 17 May 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 29 May 2015 Trial design presented at 51st Annual Meeting of the American Society of Clinical Oncology.